Bluejay Diagnostics (NASDAQ:BJDX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX) from a sell rating to a hold rating in a research report sent to investors on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bluejay Diagnostics has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of NASDAQ:BJDX opened at $0.83 on Friday. The firm’s 50 day moving average price is $1.08 and its 200 day moving average price is $1.96. The stock has a market cap of $3.72 million, a price-to-earnings ratio of -0.12 and a beta of 0.91. Bluejay Diagnostics has a fifty-two week low of $0.82 and a fifty-two week high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insider Buying and Selling at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the transaction, the insider directly owned 92,055 shares in the company, valued at $128,877. This represents a 27.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.